This is a routine 10b5-1 plan sale by a director, no material signal. The sale is small relative to market cap and consistent with prior plan activity. No immediate trading action warranted.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 12 $83.55entry
- T+1 · 6mo ago 0.00%α −0.54% · $83.55
- T+5 · 6mo ago −4.64%α −4.72% · $79.67
- T+20 · 5mo ago −6.37%α −4.64% · $78.23
- T+60 · 3mo ago +27.36%α +22.98% · $106.41
Price Chart
How similar events traded
Executive Summary
Director Elena Ridloff filed a Form 144 to sell 3,000 shares of Kymera Therapeutics common stock, with an estimated market value of approximately $258,240. The sale is planned for execution on May 11, 2026, and is part of a pre-arranged 10b5-1 trading plan, with prior sales under the same plan in March and April 2026. Given the small size relative to the company's $7.1B market cap and the use of a 10b5-1 plan, this filing is routine and carries minimal signal for traders.
Key Facts
- Insider: Director Elena Ridloff
- Shares to be sold: 3,000 shares of common stock
- Estimated value: $258,240
- Sale date: May 11, 2026
- Sale is part of a 10b5-1 trading plan established on December 11, 2025
- Prior sales under same plan: 4,600 shares on April 1, 2026 ($392,922) and 7,400 shares on March 31, 2026 ($631,739)
- Shares acquired via exercise of stock options (issuer grant, cash exercise)
Financial Impact
Approximately $258,240 in planned insider sales, representing ~0.004% of the company's $7.1B market cap
Risk Factors
- Insider selling under a 10b5-1 plan is pre-scheduled and not indicative of near-term negative views
- No additional risk from this filing alone
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-004332 |
| Document: 0001950047-26-004332-index.html | 0001950047-26-004332 |
| Document: 0001950047-26-004332.txt | 0001950047-26-004332 |
Track record
37 reports on KYMR
7 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
- Oct 29, 202618d ago 8-K Neutral 5/10 No price data
- Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
- Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
- Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
- Aug 5, 202614w ago 8-K Bullish 6/10 Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
- Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 5/10 Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers